Considering the anti-apoptotic effect exerted by PON2, it is reasonable to expect that modulating enzyme expression could greatly influence the response of cancer cells to conventional CDDP-based treatment based on the drug’s mechanism of action. The gene discussed is PON2; the disease is cancer.